Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dose escalation study of rVIIa-FP (CSL689) in hemophilia A or B patients with inhibitors
2012-001309-26Phase 2Completed
- Sponsor
- CSL Limited
- Start
- Oct 2013
- Modality
- Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, open-label trial of CSL689 in hemophilia A and hemophilia B (HB) (2 arms), sponsored by CSL Limited. Primary endpoint: Area under the curve (AUC0-t). Started Oct 2013; status: completed.
02
Drugs
CSL689
03
Conditions
hemophilia Ahemophilia B (HB)
Beyond the preview
Go deeper on 2012-001309-26.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2012-001309-26.